Trial Profile
Chidamide Combined With Cladribine/Gemcitabine/Busulfan (ChiCGB) With Autologous Stem-Cell Transplantation in High-risk Hodgkin and Non-Hodgkin Lymphoma
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Autologous stem cell therapy (Primary) ; Busulfan (Primary) ; Cladribine (Primary) ; Gemcitabine (Primary) ; Tucidinostat (Primary)
- Indications Diffuse large B cell lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 03 Aug 2018 New trial record